Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMRA-335140 in Major Depressive Disorder
NCT04221230Phase 2Completed
- Sponsor
- Neumora Therapeutics, Inc.
- Start
- Jan 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of navacaprant in major depressive disorder (MDD), sponsored by Neumora Therapeutics, Inc.. Started Jan 2020; status: completed.
02
Drugs
navacaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04221230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221230.